Bethesda, Maryland 20892

  • Brain and Central Nervous System Tumors


RATIONALE: Diagnostic procedures, such as proton nuclear magnetic resonance spectroscopic imaging and fludeoxyglucose F 18 positron emission tomography may improve the ability to detect the extent of cancer in young patients who have brain tumors. PURPOSE: This clinical trial is studying how well proton nuclear magnetic resonance spectroscopic imaging works compared to fludeoxyglucose F 18 positron emission tomography in finding tumor activity and the extent of cancer in young patients with brain tumors.

Study summary:

OBJECTIVES: Primary - Compare proton nuclear magnetic resonance spectroscopic imaging (^1H-MRSI) vs fludeoxyglucose F 18 positron emission tomography (FDG PET) scanning in determining biologic or metabolic activity in pediatric patients with brain tumors. Secondary - Correlate results of these imaging techniques with standard MRI readings and outcome in these patients. - Utilize these imaging techniques and various magnetic resonance sequences to evaluate changes over time in primary brain tumors as a result of the natural history of the lesion or therapeutic effects in these patients. OUTLINE: Patients undergo standard MRI evaluation and proton nuclear magnetic resonance spectroscopic imaging (^1H-MRSI). Within 2 weeks after ^1H-MRSI, patients then undergo fludeoxyglucose F 18 (FDG) positron emission tomography (PET) imaging. Patients may undergo repeat MRI and ^1H-MRSI scans every few months as needed. Patients undergo no more than 1 FDG PET scan per year. Patients remain on this study for up to 2 years. PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.


DISEASE CHARACTERISTICS: - Radiographically confirmed diagnosis of 1 of the following: - Brain tumor, including, but not limited to 1 of the following: - High-grade glioma - Low-grade glioma - Primitive neuroectodermal tumor - Ependymoma - Brainstem glioma - Residual abnormality (e.g., postoperatively or post-radiotherapy) of the brain - Measurable or evaluable by standard MRI or CT scan PATIENT CHARACTERISTICS: Age - 1 to 21 Performance status - Not specified Life expectancy - Not specified Hematopoietic - Not specified Hepatic - Not specified Renal - Not specified Other - Not pregnant or nursing - Negative pregnancy test - Must be a candidate for anesthesia if unable to undergo imaging study (either because of physical or psychological factor) without sedation - No diabetes mellitus - No steroid-induced hyperglycemia (i.e., fasting glucose greater than 150 mg/dL) - No history of a severe reaction (CTC grade 2 or greater) to gadolinium or other contrasting agents - No metallic MRI-incompatible implant, including any of the following: - Cardiac pacemaker - Neural pacemaker - Aneurysmal clip - Shrapnel - Cochlear implant - Ferrous surgical clip - No permanent braces, permanent retainers, or nonferrous implant that would interfere with obtaining spectroscopy in the area of the tumor, in the judgment of the principal investigator - Weight no greater than 136 kg - Weight no greater than 70 kg for patients under age 18 PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - Prior chemotherapy allowed Endocrine therapy - Concurrent steroids allowed Radiotherapy - See Disease Characteristics - Prior radiotherapy allowed Surgery - See Disease Characteristics - Prior surgery allowed Other - Current treatment regimen may be continued or changed as necessary and determined by the primary physician - Concurrent anticonvulsants or other therapies allowed



Primary Contact:

Principal Investigator
Katherine Warren, MD
NCI - Pediatric Oncology Branch

Backup Contact:


Location Contact:

Bethesda, Maryland 20892
United States

Clinical Trials Office - Warren Grant Magnusen Clinical Center
Phone: 888-NCI-1937

Site Status: Recruiting

Data Source:

Date Processed: November 27, 2022

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.